1 Min Read How Did COVID Push Immunology Forward?
July 24, 2026How Did COVID Push Immunology Forward?
July 24, 2026Three years of data worth thirty years of immunology
By the Editors Care Framework & Diagram
From genome publication to emergency authorization took 11 months — versus the usual 10–15 years. That speed is now accelerating vaccine programs for Flu, RSV, and even cancer.
People with both an infection and a vaccination develop neutralizing antibodies 3–5× higher than either alone, with better coverage against new variants — two different exposure trains broader, higher-quality memory.
Circulating antibodies fade within months, but memory B and T cells persist for years and respond within days of re-exposure — explaining why reinfection stays common while protection from severe illness holds up.
Dexamethasone became the first drug proven to reduce COVID mortality, and the anti-inflammatory protocols refined for COVID’s cytokine storms also improved how doctors manage CAR-T’s identical complication.
10–30% of infected people develop persistent symptoms, likely from some mix of lingering virus, immune dysregulation, and self-attacking antibodies — a research door that may also help explain ME/CFS and other post-infection illnesses.
- Karikó and Weissman won the 2023 Nobel Prize for the chemical modification that made mRNA vaccines possible — work rejected by funders for years before COVID proved it right.